Metabolic health monitoring has traditionally been fragmented, patients tracking glucose separately from weight, activity, and blood pressure. How is the connected devices ecosystem changing the way clinicians approach chronic disease management in India?
Metabolic health monitoring has long been approached in fragments, but clinical reality has never been that simple. A cardiac event isn’t isolated to the heart—it’s influenced by blood pressure, glucose variability, stress, sleep, and lifestyle. Similarly, diabetes extends far beyond pancreatic function. When clinicians are forced to interpret these in silos, critical context is lost.
Connected ecosystems are changing this by enabling correlation. When multiple vitals are tracked together, patterns begin to emerge linking glucose spikes to sleep, BP fluctuations to stress, or weight trends to metabolic instability. This shifts care from episodic interpretation to continuous, context-driven decision-making.
In India, this is particularly critical. With 1 in 4 adults hypertensive and nearly 1 in 10 diabetic and 50–70 per cent still undiagnosed or poorly managed, fragmented care has real consequences.
We’re now seeing clinicians move toward proactive, data-backed interventions rather than reactive treatment.
At Tracky, we’re building a unified metabolic monitoring layer bringing together continuous glucose, cardiac, and emerging biomarkers. The aim is simple: not just more data, but connected insights that drive better clinical decisions.
Continuous glucose monitors and body composition scales are still relatively niche in the Indian market. What are the biggest barriers to making real-time metabolic monitoring mainstream?
The biggest barrier isn’t technology, it’s mindset. In India, healthcare has traditionally been reactive. Most people engage with their health only when symptoms become severe, not when early signals appear. Continuous monitoring, by design, is proactive and that requires a fundamental shift.
In more mature health-tech markets, even across parts of Southeast Asia, tools like body composition scales have become part of daily routines placed in bathrooms, used as frequently as a weighing scale. In India, the same devices are still viewed as clinical or diagnostic.
Layered onto this are practical challenges. Awareness is still evolving, with both patients and clinicians accustomed to episodic data. Cost is often evaluated upfront rather than against long-term outcomes. And fragmented user experiences across devices reduce sustained engagement.
What’s encouraging is that this is beginning to change, with a growing shift toward preventive care.
At Tracky, we believe adoption will follow simplicity—when continuous monitoring becomes seamless, connected, and part of everyday life, rather than an intervention.
With India’s diabetes and obesity burden growing rapidly, how critical is the shift from episodic consultations to continuous, data-driven care and what infrastructure needs to be in place to make that shift viable at scale?
The shift isn’t just important, it’s inevitable. India is already dealing with a massive chronic burden, with nearly 1 in 10 people living with diabetes and obesity rising sharply across both urban and semi-urban populations. Yet, care delivery is still largely episodic built around infrequent consultations that capture moments, not patterns.
Chronic conditions don’t progress in snapshots. Glucose variability, weight gain, blood pressure fluctuations—these evolve daily. Without continuous visibility, clinicians are often intervening late, once complications have already set in.
Moving to data-driven, continuous care changes this dynamic entirely. It enables earlier interventions, personalised treatment adjustments, and better long-term outcomes.
But scaling this requires more than just devices. First, seamless device ecosystems that can passively capture and integrate multi-parameter data. Second, intelligent platforms that translate this data into actionable insights, not just dashboards. Third, clinical workflows that embed remote monitoring into everyday practice, without adding to the clinician’s burden.
At Tracky, we see this as building a digital infrastructure layer for metabolic health—where continuous monitoring, AI-led insights, and clinical validation come together to make proactive care scalable.
Tracky integrates data from CGMs, body composition scales, and blood pressure monitors into a single unified dashboard. What was the core clinical problem you were solving when designing this correlated view, and how does it change the quality of decisions a doctor can make between patient visits?
The core problem we set out to solve was lack of clinical context. Doctors weren’t short on data—they were short on connected insights. Glucose, weight, blood pressure—all existed, but in isolation, making it difficult to understandwhysomething was happening, not justwhat.
At Tracky, we built a correlated ecosystem—integrating CGMs, body composition, BP monitors, and fitness wearables to capture HRV, sleep, activity, and stress. Because metabolic health is not a single metric; it’s the interaction of many.
But the real shift comes from our interpretation layer. Through Tracky’s clinical analysis platform, doctors don’t just see data—they see continuously interpreted, real-time patient profiles across their population. This allows them to identify risk earlier, prioritize patients who need intervention, and act with far greater precision between visits.
A glucose spike is no longer just a number—it’s contextualised with sleep debt, stress load, or activity changes.
The goal is simple: move from reactive consultations to continuous, insight-led care—where clinicians can intervene at the right time, with the right approach.
Tracky sits at the intersection of connected devices and real-time monitoring software. How do you see this integrated ecosystem evolving and what role do you see Tracky playing as India’s GLP-1 market scales rapidly over the next two to three years?
We see the ecosystem evolving from connected devices to connected Health intelligence. Today, most platforms still focus on collecting data. The next phase is about interpreting it in real time, correlating multiple biomarkers, and embedding that intelligence directly into clinical workflows.
This becomes especially important with the rise of GLP-1 therapies in India. While these drugs are powerful, their outcomes are highly variable—dependent on adherence, lifestyle, metabolic response, and side effects. Without continuous monitoring, clinicians are still operating with limited visibility between consultations.
This is where an integrated ecosystem becomes critical. Real-time data across glucose, weight, body composition, HRV, and activity can help track how a patient is actually responding to therapy—not just whether they are on it. It allows for more precise dose adjustments, better patient stratification, and early identification of non-responders or potential risks.
At Tracky, we see ourselves as the infrastructure layer that sits alongside therapeutics. As GLP-1 adoption scales, our role is to ensure that outcomes scale with it—by enabling continuous, data-driven management rather than episodic intervention.
Because the future isn’t just about access to treatment—it’s about measurable, optimised outcomes.
[emailprotected]
[emailprotected]